ZyVersa Therapeutics, Inc. announced publication of an article in the peer-reviewed Journal of the American Heart Associationadd addressing the role of NLRP3 inflammasomes in PAD. ZyVersa's Inflammasome ASC Inhibitor IC 100 inhibits the inflammasome adaptor protein ASC, a component of multiple types of inflammasomes including NLRP3 inflammasome inflammasomes. In the paper titled, "NLRP3 Inflammasome Activation in Peripheral Arterial Disease," the authors evaluated human peripheral arteries from patients undergoing limb amputation and serum collected prior to surgery.

Data demonstrated an association between NLRP3, macrophage accumulation, and calcification in arteries of patients with PAD, suggesting that NLRP3 inflammasom activation may be a driver of the disease. Following are key findings reported in the paper: NLRP3 protein was significantly increased in vessels from patients with PAD compared with control vessels, and it was present in macrophages in the vicinity of calcification, along with IL-1b and caspase-1. Likewise, serum NRLP3 protein levels and IL-1b were significantly increased in PAD patients compared to controls, suggesting activation of NLRP3 Inflammasomes both locally and systemically. The authors stated, "Given that PAD is associated with increased risk of cardiac comorbidity and cardiac and vascular ischemic events, further studies are now needed to determine the clinical implication of pharmacologically reducing vascular inflammation in this cohort before surgical intervention.